# Influence of Clopidogrel on the Pharmacodynamics and Safety of Terbogrel in Healthy Male Subjects

> **NCT02222987** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 14 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Terbogrel
- **DRUG:** Clopidogrel

## Key facts

- **NCT ID:** NCT02222987
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-02
- **Primary completion:** 1999-03
- **Final completion:** —
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2014-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02222987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02222987, "Influence of Clopidogrel on the Pharmacodynamics and Safety of Terbogrel in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02222987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*